RE:RE:RE:RE:pg will only be prescribed at a few highly specializedGiven that in rare diseases, there are very well functioning patient associations such as Alstrom and IPF, if a new drug is approved the marketing of it will likely be a straight forward affair. Also, pulmonary disease specialists are going to be looking for alternatives to Esbriet and ofev, given the low level of take-up of these drugs because of the nasty side effects. Marketing and sales of 4050 for these types of patient populations is so not going to be an issue for even a small company like Prometic which will be targeting potential sales of $2-3B in IPF alone.